Genital herpes cannot be permanently eliminated from the body. The virus embeds itself in nerve cells near the base of the spine, where it remains dormant between outbreaks, hidden from both the immune system and current medications. But while there is no cure, antiviral treatment can dramatically reduce outbreaks, shorten the ones that do occur, and lower the chance of passing the virus to a partner. For many people, the right treatment plan makes herpes a minor, infrequent inconvenience rather than a defining health issue.
Why the Virus Can’t Be Fully Removed
During the initial infection, herpes simplex virus travels along nerve fibers from the skin’s surface into clusters of nerve cells called sensory ganglia. For genital herpes, this is typically the dorsal root ganglia near the lower spine. Once inside a neuron, the virus essentially goes to sleep. It stops replicating and produces only a small transcript that helps keep the nerve cell alive and the virus safely tucked away. Because it isn’t actively making copies of itself during this dormant phase, antiviral drugs, which work by blocking viral replication, have nothing to target.
Periodically, triggers like stress, illness, fatigue, or hormonal shifts wake the virus up. It travels back down the nerve fiber to the skin, where it can cause sores or, more often, shed invisibly without symptoms. This cycle of dormancy and reactivation is why herpes persists for life, and why treatment focuses on managing outbreaks rather than eliminating the infection.
Antiviral Medications for Outbreaks
Three prescription antivirals form the backbone of herpes treatment: acyclovir, valacyclovir, and famciclovir. All three work by the same basic mechanism, interrupting the virus’s ability to copy its DNA during an active outbreak. Valacyclovir and famciclovir are newer formulations that the body absorbs more efficiently, meaning fewer pills per day.
For a first outbreak, the CDC recommends a 7 to 10 day course of any of these medications, with the option to extend treatment if sores haven’t fully healed. First episodes tend to be the most severe, often with widespread sores, flu-like symptoms, and swollen lymph nodes, so starting medication as early as possible matters. If you recognize the early warning signs of a recurrent outbreak (tingling, itching, or soreness before sores appear), taking medication at that point can shorten the episode by several days or even prevent visible sores from forming.
Daily Suppressive Therapy
If you experience frequent outbreaks, typically defined as six or more per year, daily antiviral medication can change the picture considerably. Suppressive therapy means taking a lower dose of an antiviral every day, regardless of whether you have symptoms. Clinical data shows this approach reduces outbreak frequency by 70 to 80 percent for most people. Some people on daily therapy go years without a single recurrence.
Suppressive therapy also cuts down on asymptomatic shedding, the periods when the virus reaches the skin surface without causing noticeable symptoms. With HSV-2, shedding occurs on roughly 34 percent of days in the first year after infection and still about 17 percent of days a decade later. Daily antivirals reduce this shedding significantly, which is one reason suppressive therapy is often recommended for people whose partners don’t have herpes. Many people stay on suppressive therapy for years with minimal side effects, though it’s worth reassessing with a provider periodically since outbreak frequency naturally declines over time for most people.
Comfort Measures During an Outbreak
Medication handles the virus itself, but there are practical steps that ease discomfort while sores heal. Cool compresses applied to sores several times a day help with both pain and itching. Keeping the area clean with gentle soap and water, then patting dry rather than rubbing, prevents secondary bacterial infection. Sores heal fastest when left uncovered and exposed to air, so skip bandages.
Loose, breathable cotton underwear reduces friction and moisture buildup. Synthetic fabrics and tight pants trap heat and can make irritation worse. Women with sores on the labia sometimes find that urinating in a shallow bath of warm water prevents the stinging that comes from urine contacting open sores. Over-the-counter pain relievers like ibuprofen can take the edge off if sores are particularly tender.
Reducing Transmission Risk
Even without a cure, the combination of daily antivirals and condoms substantially lowers the odds of passing herpes to a sexual partner. Suppressive therapy alone cuts transmission risk by about half. Adding consistent condom use reduces it further, though condoms don’t cover all potentially affected skin. Avoiding sexual contact during active outbreaks, including the prodromal tingling phase before sores appear, is the single most effective step for preventing transmission.
It’s worth knowing that asymptomatic shedding accounts for a significant share of new transmissions. Many people pass the virus when they have no visible symptoms and don’t realize they’re infectious. This is why daily suppressive therapy matters for transmission prevention, not just outbreak control.
The Trajectory Over Time
For most people with genital herpes, outbreaks become less frequent and less severe as the years pass. The immune system gets better at suppressing reactivation, and the viral shedding rate drops. The first year is almost always the worst. Many people who initially have several outbreaks a year find that by year three or four, episodes are rare, brief, and mild, sometimes just a small patch of irritation that resolves in a few days.
This natural decline means that someone who needs daily suppressive therapy early on may eventually be able to switch to episodic treatment, taking medication only when an outbreak begins. The emotional weight of a diagnosis also tends to lighten with time, as people learn their own patterns, identify their triggers (common ones include stress, sleep deprivation, friction during sex, and menstruation), and realize how manageable the condition actually is in practice.
Therapeutic Vaccines in Development
Several companies are developing therapeutic vaccines designed not to prevent infection but to reduce outbreaks and shedding in people who already carry the virus. Moderna completed a Phase 1/2 trial of an mRNA-based therapeutic vaccine for HSV-2 in early 2025, though results have not yet been published. Other approaches using gene-editing technology aim to target and disable the dormant virus inside nerve cells directly. None of these are available yet, but the pipeline is more active than it has been in decades.